Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Colorcon
McKinsey
Moodys
Johnson and Johnson
Boehringer Ingelheim
AstraZeneca

Last Updated: May 26, 2022

ZEVALIN Drug Profile


✉ Email this page to a colleague

« Back to Dashboard

Recent Clinical Trials for ZEVALIN

Identify potential brand extensions & biosimilar entrants

SponsorPhase
JDP Therapeutics, Inc.Phase 2
TerSera TherapeuticsPhase 2
TerSera Therapeutics LLCPhase 2

See all ZEVALIN clinical trials

Recent Litigation for ZEVALIN

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
AbbVie Inc. v. Alvotech hf.2021-05-28
Alvotech USA Inc. v. Abbvie Inc2021-05-11
GENENTECH, INC. v. CELLTRION, INC.2018-01-11

See all ZEVALIN litigation

PTAB Litigation
PetitionerDate
2017-12-20

See all ZEVALIN litigation

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. General brand-side disclosures
  4. These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for ZEVALIN Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for ZEVALIN Derived from Company Disclosures

These patents were obtained from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Patent No. Estimated Patent Expiration Source
Acrotech Biopharma Llc ZEVALIN ibritumomab tiuxetan Injection 125019 See Plans and Pricing 2015-04-07 Company disclosures
Acrotech Biopharma Llc ZEVALIN ibritumomab tiuxetan Injection 125019 See Plans and Pricing 2015-07-07 Company disclosures
Acrotech Biopharma Llc ZEVALIN ibritumomab tiuxetan Injection 125019 See Plans and Pricing 2015-12-01 Company disclosures
Acrotech Biopharma Llc ZEVALIN ibritumomab tiuxetan Injection 125019 See Plans and Pricing 2039-03-29 Company disclosures
Acrotech Biopharma Llc ZEVALIN ibritumomab tiuxetan Injection 125019 See Plans and Pricing 2019-06-04 Company disclosures
Acrotech Biopharma Llc ZEVALIN ibritumomab tiuxetan Injection 125019 See Plans and Pricing 2021-01-27 Company disclosures
Acrotech Biopharma Llc ZEVALIN ibritumomab tiuxetan Injection 125019 See Plans and Pricing 2019-03-01 Company disclosures
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Patent No. >Estimated Patent Expiration >Source

3) Low Certainty: US Patents for ZEVALIN Derived from Patent Text Search

These patents were obtained by searching patent claims

Supplementary Protection Certificates for ZEVALIN

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
SPC/GB04/025 United Kingdom See Plans and Pricing PRODUCT NAME: IBRITUMOMAB COMPRISING A CHELATING AGENT FOR YTTRIUM (90); REGISTERED: UK EU/1/03/264/001 20040116
132004901230024 Italy See Plans and Pricing PRODUCT NAME: IBRITUMOMAB(ZEVALIN); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/03/264/001, 20040116
122009000070 Germany See Plans and Pricing PRODUCT NAME: RITUXIMAB; NAT. REGISTRATION NO/DATE: EU/1/98/067/001-002 19980602; FIRST REGISTRATION: CH IKS 54378 01 19971127
CA 2009 00043 Denmark See Plans and Pricing PRODUCT NAME: RITUXIMAB; NAT. REG. NO/DATE: EU 1/98/067/001-002 19980602; FIRST REG. NO/DATE: CH IKS 54378 01 19971127
C00669836/01 Switzerland See Plans and Pricing FORMER OWNER: BIOGEN INC., US
SZ 16/2004 Austria See Plans and Pricing PRODUCT NAME: IBRITUMOMAB TIUXETAN
C300424 Netherlands See Plans and Pricing PORDUCT NAME: RITUXIMAB; NAT. REGISTRATION NO/DATE: 19980602; FIRST REGISTRATION: CH IKS 54378 01 19971127
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
AstraZeneca
Harvard Business School
Moodys
Boehringer Ingelheim
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.